Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
narmafotinib + olomorasib
- Development stage
- Unknown
- Lead developer
- Amplia Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Narmafotinib + Olomorasib is an investigational small molecule combination therapy being developed by Amplia Therapeutics in collaboration with Eli Lilly. The combination pairs Amplia's highly potent and selective focal adhesion kinase (FAK) inhibitor, narmafotinib (AMP945), with Eli Lilly's next-generation, covalent KRAS G12C inhibitor, olomorasib (LY3537982). FAK activation has been identified as a key mediator of adaptive resistance to KRAS G12C inhibitors, promoting tumor cell survival and remodeling the tumor microenvironment. By combining FAK and KRAS G12C inhibition, this dual-targeted approach aims to overcome resistance mechanisms, thereby deepening and prolonging therapeutic responses. The combination is being evaluated in a Phase 1b/2b clinical trial as a second-line treatment for patients with advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC).
- Other names
- AMP-945 + LY-3537982AMP945 + LY3537982narmafotinib plus olomorasib
02
Targets
FAK (Focal adhesion kinase)KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)
Beyond the preview
Go deeper on narmafotinib + olomorasib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on narmafotinib + olomorasib.